Drug firm Zydus Cadila today said Zydus Hospira Oncology, a JV between the company and Hospira Inc, has received Establishment Inspection Report (EIR) from the US health regulator for its Ahemdabad manufacturing facility.
The EIR from the United states Food and Drug Administration (USFDA) has concluded that the inspection is closed but has also said that the inspection classification of this facility is 'voluntary action indicated' (VAI).
According to the USFDA, VAI means that though objectionable conditions were found and documented, but the agency is not prepared to take or recommend regulatory action.
Zydus Hopsira Oncology is a 50:50 joint venture company between Zydus Cadila and Hospira Inc USA (now part of Pfizer Group), Zydus Cadila said.
The manufacturing plant had completed the USFDA audit from April 5 to April 12, 2018, it added.
Shares of Cadila Healthcare, the listed entity of the group, were ended at Rs 366.30 per scrip in the afternoon trade on BSE, down 1.40 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app